for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

メルク

MRCG.DE

現在値

184.00EUR

変化

-1.95(-1.05%)

出来高

143,029

本日のレンジ

182.95

 - 

187.85

52週レンジ

153.10

 - 

231.50

∙ 約20分前の相場を表示しています。

適時開示

Merck KGaA Says It Has Seen Strong Recovery In China Since June

Aug 4 (Reuters) - Merck KGaA <MRCG.DE>::CEO - STRONG RECOVERY IN CHINA SINCE JUNE AFTER THE LOCKDOWNS THERE.CEO: WE DON'T SEE A MAJOR RISK TO OUR 2022 OUTLOOK FROM POTENTIAL GAS SHORTAGES IN EUROPE.CEO: IN A SCENARIO WHERE WE WOULD NEED TO REDUCE OUR GAS CONSUMPTION IN EUROPE BY 50% AND REPLACE THIS THIS 50-50 WITH OIL AND ELECTRICITY WE WOULD BE FACED WITH EXTRA COSTS IN THE LOW TO MID-DOUBLE-DIGIT MILLION EURO RANGE.Further company coverage: <MRCG.DE>. ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).

Merck Healthcare Reports 8.3% Passive Stake In Moonlake Immunotherapeutics

Aug 3 (Reuters) - Merck Healthcare::MERCK HEALTHCARE KGAA REPORTS 8.3% PASSIVE STAKE IN MOONLAKE IMMUNOTHERAPEUTICS AS OF AUGUST 6 - SEC FILING.Further company coverage: MLTX.O. ((Reuters.Briefs@thomsonreuters.com;)).

Merck And Micron Join Forces For Sustainable Gas Solutions In Semiconductor Industry

Aug 3 (Reuters) - MERCK KGAA <MRCG.DE>::MERCK KGAA, DARMSTADT, GERMANY AND MICRON JOIN FORCES FOR MORE SUSTAINABLE GAS SOLUTIONS IN SEMICONDUCTOR INDUSTRY.PARTNERSHIP TO DEVELOP GAS SOLUTIONS WITH A LOW GLOBAL WARMING POTENTIAL (GWP) USED IN PRODUCTION OF SEMICONDUCTORS.

Merck KGaA Announces Collaboration With Agilent Technologies

June 14 (Reuters) - Merck KGaA <MRCG.DE>::MERCK KGAA - ANNOUNCES COLLABORATION WITH AGILENT TECHNOLOGIES TO FILL INDUSTRY GAP IN PROCESS ANALYTICAL TECHNOLOGIES FOR DOWNSTREAM PROCESSING.

Merck KGaA Invests More Than EUR 440 Mln And Expands Its Membrane And Filtration Manufacturing In Ireland

May 23 (Reuters) - MERCK KGAA <MRCG.DE>::MERCK INVESTS MORE THAN €440 MILLION AND EXPANDS ITS MEMBRANE AND FILTRATION MANUFACTURING IN IRELAND.COMPANY TO INVEST IN TWO MAJOR LIFE SCIENCE PROJECTS OVER FIVE YEARS.INVESTMENT CREATES MORE THAN 370 JOBS BY THE END OF 2027.

Merck Invests EUR 100 Mln To Accelerate Single-Use Manufacturing In China

April 29 (Reuters) - MERCK KGAA <MRCG.DE>::MERCK INVESTS APPROXIMATELY EUR 100 MILLION TO ACCELERATE SINGLE-USE MANUFACTURING IN CHINA.PARTNERSHIP WITH ADMINISTRATIVE MANAGEMENT COMMITTEE OF WUXI NATIONAL HIGH-TECH INDUSTRIAL DEVELOPMENT ZONE TO JOINTLY CULTIVATE AND ENHANCE THE LIFE SCIENCE ECOSYSTEM IN WUXI.PLANS TO INVEST APPROXIMATELY EUR 100 MILLION (RMB 700 MILLION OR USD 110 MILLION) OVER SIX YEARS BY EXPANDING EXISTING WUXI PRODUCTION SITE TO SIGNIFICANTLY INCREASE BIOPHARMA SINGLE-USE ASSEMBLIES AND CUSTOM DESIGN CAPABILITIES.INVESTMENT IS EXPECTED TO CREATE ABOUT 1,000 NEW POSITIONS AND BE OPERATIONAL BY 2024.Further company coverage: MRCG.DE. (Gdansk Newsroom). ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;)).

Merck Acquires MAST Platform

April 6 (Reuters) - MERCK KGAA <MRCG.DE>::SAID ON TUESDAY IT HAS ACQUIRED THE MAST® (MODULAR AUTOMATED SAMPLING TECHNOLOGY) PLATFORM FROM LONZA.THE FINANCIAL DETAILS OF THE DEAL WERE NOT DISCLOSED. Further company coverage: MRCG.DE. (Gdansk Newsroom). ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;)).

Merck - Glucophage First Oral Diabetes Treatment Approved In Europe For Use During Pregnancy

Feb 28 (Reuters) - Merck KGaA <MRCG.DE>::GLUCOPHAGE® IS FIRST ORAL DIABETES TREATMENT APPROVED IN EUROPE FOR USE DURING PREGNANCY.Further company coverage: <MRCG.DE>. ((frankfurt.newsroom@thomsonreuters.com;)).

Merck Completes Acquisition Of Exelead

Feb 24 (Reuters) - MERCK KGAA <MRCG.DE>::ANNOUNCED ON WEDNESDAY IT HAS COMPLETED THE ACQUISITION OF EXEALED FOR APPROXIMATELY USD 780 MLN IN CASH.PLANS TO FURTHER INVEST EUR 500MLN TO SCALE UP EXELEAD'S TECHNOLOGY OVER THE NEXT TEN YEARS. Further company coverage: MRCG.DE. (Gdansk Newsroom). ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;)).

Quris Says Entered Into Option Agreement With Merck KGaA On Co's BioAI Platform For Clinical Safety Prediction

Feb 9 (Reuters) - :QURIS SAYS ENTERED INTO OPTION AGREEMENT WITH MERCK KGAA ON CO'S BIOAI PLATFORM FOR CLINICAL SAFETY PREDICTION.QURIS SAYS MERCK CAN OBTAIN UP TO 5-YEAR EXCLUSIVE LICENSE TO SPECIFIC DISEASE DOMAIN; UPON MERCK EXERCISING OPTION, CO MAY RECEIVE UNDISCLOSED AMOUNT‍.QURIS SAYS PROJECT ALLOWS MERCK TO ASSESS CO’S PLATFORM WITH INITIAL ASSESSMENT TO IDENTIFY POTENTIAL LIVER TOXICITY RISKS FOR DRUG CANDIDATES. ((Reuters.briefs@thomsonreuters.com;)).

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up